CopenDapp Labs is focusing its 2026 build around SponCite: verified site-readiness profiles, transparent matching, and CDA-gated feasibility — with a roadmap toward translational R&D workflows.
We start with the painful wedge: helping sponsors find, qualify, and engage the right research sites through current readiness evidence, transparent matching, and CDA-gated feasibility — then expand toward study setup and operational workflows as the roadmap matures.
Prototype snapshot
Sponsors see structured feasibility responses, readiness risks, assumptions, and evidence trails. Sites keep agency over their profile and current constraints.
Emerging biotech, medtech, CRO, or research teams planning high-stakes site discovery or feasibility work.
Clinical operations, preclinical operations, regulatory, and study-startup experts who want to shape the workflow.
People who believe study operations need a site-agency-first AI-native operating layer.
Roadmap / vision — not claimed as built today
SponCite starts where mid-market sponsors and sites feel the pain today: finding the right site, proving readiness, and running feasibility. The roadmap expands from that data loop into study setup, shared planning, documents, startup, financials, and intelligence — one validated phase at a time.
$1.2B → $3.5B
AI feasibility wedge
$16B → $31B
Broader eClinical layer
Zero PHI first
Limited-risk wedge posture
Roadmap expansion
Launching wedge
Verified site-readiness profiles, transparent matching, CDA-gated feasibility, and engagement tracking.
Next expansion
Map protocols onto ICH M11 / CPT / DDF-style structures, derive requirements, and cascade into feasibility.
Operational layer
Sponsor and site see the same plan: Gantt, dependencies, forecast finish dates, and critical-path signals.
Document foundation
Versioned documents, expected-document lists, site file checklists, templated forms, and gap-first dashboards.
Regulated future
Non-PHI eCRF builder first; PHI runtime, safety, autonomous agents, and evidence graph only behind hard gates.
Current prototype direction
AI-assisted study criteria are turned into transparent, reviewable site filters and shortlists.
Sponsors see why a site fits: therapeutic alignment, equipment, verification, readiness, and evidence freshness.
Structured feasibility responses make sponsor-site conversations auditable and reusable without exposing PHI.
Sites manage their readiness profile, active opportunities, gaps, and feasibility workload from their own view.
The public promise stays grounded: today’s wedge is discovery, readiness, transparent matching, feasibility, and engagement. The larger translational R&D OS is the north-star roadmap, earned through pilots, advisors, compliance partners, and validated customer pull.
AI-native study operations need a site-agency-first layer
Clinical research teams are adopting AI for planning, feasibility, and operational coordination.
Yet site capability data is still fragmented across spreadsheets, public registries, inboxes, and relationship networks.
Sites are often treated as passive records instead of active operators with current readiness evidence.
SponCite starts with the wedge that creates the data loop: site discovery, CDA-gated feasibility, and transparent evidence-based matching.
SponCite is starting where uncertainty is sharpest: finding the right sites, connecting securely, and turning feasibility into reusable readiness evidence.
Verified site-readiness profiles, study builder, matching, and feasibility workflows
Protocol requirements, readiness gaps, documents, and sponsor-site collaboration
Human-reviewed agents, evidence graph, and translational intelligence as the data moat compounds
SponCite is the flagship. ProsperPals and gameAIgents remain active product tracks, but 2026 go-to-market focus is clinical study discovery and feasibility.
Site-agency-first study discovery and feasibility
Flagship platform for verified site-readiness profiles, sponsor study discovery, transparent evidence-based matching, and CDA-gated feasibility — with a roadmap toward translational R&D operating workflows.
Live SponCite UI directions from the current Phase 1a prototype.
Sponsor Dashboard
Click to view public demo
Portfolio view for active trials, shortlisted sites, and pending feasibility work.
Trial Planner Cascade with AI
Click to view public demo
Guided protocol setup with AI suggestions, audit activity, and live match preview.
Glass Box Matching
Click to view public demo
Transparent scoring across clinical fit, equipment, verification, and enrollment signals.
DEVELOPMENTPrompt-to-Game Creator Studio
AI-powered game creation platform using Godot-centered workflows. gameAIgents is focused on turning prompts into playable builds with agent-assisted compile, test, and iteration loops for creators and small teams.
DEVELOPMENTAI-First Financial Companion
Privacy-first personal finance companion for younger users. ProsperPals is being built around Goldie and Fin, receipt-first capture, manual finance tracking, trust lanes, and Denmark-first alpha validation.
Product progress, market positioning, and founder-led notes from the build.
The portfolio focus is shifting toward SponCite: an site-agency-first study discovery and feasibility platform built around verified readiness profiles, transparent matching, and CDA-gated sponsor-site workflows.
Sponsors need current, evidence-backed readiness signals. Sites need agency over how their capabilities, constraints, and availability are represented. SponCite starts with that wedge: transparent matching and CDA-gated feasibility before broader study-operations expansion.
The ProsperPals alpha is focused on durable trust lanes: receipt-lineage proof, duplicate-confirmation suppression, actor-scoped audit trails, and a Denmark-first flow without live bank sync.
gameAIgents is progressing through a prompt-to-game studio workflow, with current validation centered on hosted access, deployment parity, and prompt-to-compile iteration loops.
Experienced team with proven track records in AI, gaming, and financial technology
Founder & CEO
Innovation catalyst reimagining the relationship between humans and software. Uniting expertise in AI, blockchain, and product strategy to create conversational experiences that turn complexity into simplicity. Leading the charge toward a future where technology truly speaks your language.
Head of Design & Marketing
Creative visionary behind ProsperPals app, leading the product and user experience design. Passionate about building brands and products that resonate with Gen Z audiences and beyond.
Head of Game Dev & Sales
Game industry expert with deep knowledge of gamification principles that lead to strong user engagement through leveling up rewards. Combines technical expertise behind viral engagement that drive sales and adoption.
Focused on proof, pilots, and founder-led market education before public launch
Focused Opportunity
Across clinical site selection, finance apps, and game creation tools
Flagship Focus
Clinical trial site matching is the lead 2026 product
Products Pipeline
SponCite, ProsperPals, and gameAIgents
Pre-Seed Target
To reach MVP and first 10K users
Build Stage
Founder proofs, build stories, and pilot readiness
Revenue Target
SponCite first paying customer north star
Focused Product Opportunity
SponCite adds a focused healthtech wedge to the broader AI product portfolio.
Company Founded
May 2025
SponCite PRD & Strategy Locked
Q1 2026
SponCite Build Stories Active
Q2 2026
ProsperPals Hosted Alpha Proof
Q2 2026
gameAIgents Founder Proof
Q2 2026
SponCite First Paying Customer Target
Q4 2026
We're preparing SponCite for pilot conversations while continuing focused proof work on ProsperPals and gameAIgents. The current pre-seed target is 3,4 kr M to accelerate product validation, compliance readiness, and go-to-market execution.
Proof & Pilot Prep
Compliance Readiness
First Revenue Target
Disclaimer: This information is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any securities. Investment decisions should be based on your own due diligence and consultation with qualified investment professionals. Past performance is not indicative of future results.
For SponCite, we are looking for pilot customers, clinical/preclinical advisors, and investor or ecosystem partners who want to help shape site-agency-first study operations.
Use DAIsy for a quick overview, or send the form for pilot, advisor, partner, or investor conversations.
Listen to our latest insights on AI-powered innovation
Status: Paused